Tradestie Institutional Equity Comparison Engine

NDRA vs CDNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDNA Overall Edge

CDNA Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NDRA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CDNA at 47.1x Forward P/E and 1.6% operating margin (+39.3% YoY). In options structure, NDRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDNA sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CDNA
NDRA N/M vs CDNA 47.1x Fwd P/E
Growth & Margin Winner CDNA
Op Margin 0.0% vs 1.6% ยท YoY +0.0% vs +39.3%
Momentum & Technical Winner CDNA
1Y -32.7% vs +364.5% ยท 52W Pos 37% vs 77%
Options & Structure Winner CDNA
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (18th %ile IV)
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
1M Return -6.75%
1Y Return -32.72%
Forward P/E N/M
Unified AI Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
CDNA NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
1M Return +15.19%
1Y Return +364.52%
Forward P/E 47.1x
Unified AI Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NDRA -32.72% CDNA +364.52% Spread: +397.24 pp (CDNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NDRA Revenue CDNA Revenue NDRA Op. Margin CDNA Op. Margin Margin Edge
FY2018 $0M $80M -146080.5% -20.3% CDNA
FY2019 N/A $130M N/A -19.3% CDNA
FY2020 N/A $190M N/A -11.7% CDNA
FY2021 N/A $300M N/A -10.0% CDNA
FY2022 N/A $320M N/A -24.0% CDNA
FY2023 N/A $280M N/A -72.5% CDNA
FY2024 N/A $330M N/A 12.2% CDNA
FY2025 N/A $380M N/A -8.1% CDNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NDRA (2) vs CDNA (8)
Institutional Metric NDRA CDNA Criterion Row Winner
Market Capitalization Scale $6.6M $4.1B Larger Scale CDNA
Trailing P/E Ratio Valuation N/M 32.9x Lower Multiple CDNA
Forward P/E Ratio Valuation N/M 47.1x Lower Multiple CDNA
Revenue Growth (YoY) Growth +0.0% +39.3% Higher Growth CDNA
Operating Margin (TTM) Profitability 0.0% 1.6% Higher Margin CDNA
Net Profit Margin Profitability 0.0% 25.9% Higher Margin CDNA
Return on Equity (ROE) Capital Efficiency -152.0% 33.0% Higher ROE CDNA
52-Week Range Position Momentum 37% ($3โ€“$7) 77% ($15โ€“$91) Stronger Trend CDNA
Beta / 30D Volatility Risk Regime 0.71ฮฒ ยท 48% Vol 1.21ฮฒ ยท 98% Vol Lower Realized Risk NDRA
Unified Institutional Score Composite Signal 44.7 / 100 (HOLD) 24.5 / 100 (STRONG SELL) Higher Composite NDRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NDRA vs CDNA Buy Guide
NDRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NDRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
30d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live CDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NDRA nor CDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.